28 citations
,
September 2021 in “JAAD Case Reports” This study reports that the Pfizer-BioNTech COVID-19 vaccine showed 52% protection against COVID-19 after the first dose and 95% after the second in phase 3 trials.
9 citations
,
January 2023 in “Journal of Cutaneous Immunology and Allergy” This case report describes a 37-year-old woman who developed widespread hair loss following the BNT162b2 mRNA vaccine, which mostly recovered after topical corticosteroid treatment.
May 2022 in “International Journal of Dermatology” This report describes a case of alopecia areata presenting as Marie Antoinette syndrome shortly after Pfizer/BioNTech COVID-19 vaccination, with hair regrowth and partial repigmentation following treatment.
3 citations
,
January 2023 in “Skin appendage disorders” This study reported five cases of alopecia areata following COVID-19 vaccination, with one patient experiencing worsening symptoms with each vaccine booster.
November 2025 in “Cureus” This study found that COVID-19 vaccines were generally well-tolerated among Bangladeshi medical students, with most side effects being mild and decreasing in frequency after subsequent doses.
